Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial of ABT-301, in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer

Next Previous
Trial Profile

A Phase 2 clinical trial of ABT-301, in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABT 301 (Primary) ; Tislelizumab (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 27 Sep 2024 According to an AnBogen Therapeutics media release, the clinical trial will be conducted in multiple centers and will evaluate the safety, tolerability, and preliminary efficacy of the combination therapy in patients with advanced MSS CRC. The study is expected to begin enrollment in the first quarter of 2025.
  • 27 Sep 2024 According to an AnBogen Therapeutics media release, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301 with with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair-proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in a global Phase II trial. Under the terms of the agreement , BeiGene will supply tislelizumab to Anbogen for the study.
  • 01 Jul 2024 According to an AnBogen Therapeutics media release, the company announced successful closing of a USD 7.3M oversubscribed A+ round financing which will primarily be used to support the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top